MedPal AI gets FDA approval for Mounjaro heart protection
MedPal AI PLC said the FDA approved tirzepatide (Mounjaro) to cut the risk of heart attack and stroke in type 2 diabetes, expanding its GLP-1 market reach.
MedPal AI plc ("MedPal", the "Company" or the "Group") said on 01 September 2026 that the FDA approved tirzepatide to cut the risk of heart attack and stroke in type 2 diabetes, expanding the GLP-1 market. The source text also referred to El…